GO:0030881 beta-2-microglobulin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030881 beta-2-microglobulin binding is a molecular function describing the selective binding of a protein or peptide to beta-2-microglobulin (B2M).
• B2M is the invariant light chain of MHC class I and a key player in antigen presentation, immune recognition, and serum protein homeostasis.
• Binding interactions with B2M are central to antibody recognition, peptide-based sensor design, and amyloid aggregation mechanisms.
• Dysregulated B2M binding is linked to systemic lupus erythematosus, dialysis-related amyloidosis, and kidney injury.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of B2M-binding interfaces.
• High-throughput binding assays, structural biology, and computational evolution are used to study and engineer B2M-binding proteins.
Description
GO:0030881 beta-2-microglobulin binding is a Gene Ontology molecular function term defined as the selective interaction of a protein or peptide with beta-2-microglobulin (B2M). B2M is a small, secreted protein that serves as the invariant light chain of MHC class I molecules and is present in serum and other body fluids. This binding function is essential for immune surveillance, antigen presentation, and the regulation of B2M levels in circulation. Researchers study B2M binding to understand how antibodies recognize antigens, how peptides can be engineered for biosensors, and how B2M aggregation leads to amyloid disease. The term encompasses both physiological interactions, such as those with MHC class I heavy chains and antibodies, and engineered binding events used in biotechnology. Because B2M is implicated in autoimmune diseases, kidney injury, and dialysis-related amyloidosis, understanding its binding partners has direct clinical relevance. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a research-grade overview of GO:0030881, its mechanisms, associated genes, disease links, and experimental methods.
beta-2-microglobulin binding At A Glance
| GO ID | GO:0030881 |
|---|---|
| GO term | beta-2-microglobulin binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Selective binding to beta-2-microglobulin (B2M) |
| Related molecules | MHC class I heavy chain, antibodies, engineered peptides |
| Disease relevance | Systemic lupus erythematosus, dialysis-related amyloidosis, kidney injury |
| Research methods | CRISPR screens, structural biology, binding assays, computational design |
What Is GO:0030881?
In our own words, GO:0030881 beta-2-microglobulin binding describes the molecular function of a protein or peptide selectively binding to beta-2-microglobulin (B2M). This interaction can be part of immune recognition, such as antibody-antigen complexes, or engineered binding events in sensor design. The term is a molecular_function in the Gene Ontology and does not imply a specific biological outcome; rather, it captures the binding event itself.
Why Is beta-2-microglobulin binding Important in Cell Biology?
GO:0030881 beta-2-microglobulin binding is important because B2M is a central component of the immune system and a biomarker for kidney function and autoimmune activity. Binding interactions with B2M determine how antibodies recognize antigens, how MHC class I complexes assemble, and how B2M aggregates in amyloid diseases. Understanding these interactions can inform the design of therapeutic antibodies, biosensors, and inhibitors of B2M aggregation.
• B2M binding is essential for MHC class I antigen presentation and immune surveillance.
• Antibody-B2M complexes reveal molecular basis of antigen recognition.
• Engineered B2M-binding peptides enable nanopatterned surface sensors.
• B2M aggregation into amyloid fibrils is linked to dialysis-related amyloidosis.
• Serum B2M binding activity is altered in systemic lupus erythematosus.
• Urinary B2M is a marker of kidney injury and declines after nephrectomy.
• CRISPR screens can identify genes regulating B2M binding and presentation.
• Computational evolution optimizes B2M-binding peptides for diagnostics.
• Structural studies of B2M-antibody complexes guide therapeutic design.
• B2M binding is a target for protein nanoparticle adsorbents.
Molecular Mechanism of beta-2-microglobulin binding
Binding interface and structural determinants
In simple terms: The shape and chemical properties of the binding surface determine how tightly a protein sticks to B2M.
The crystal structure of the B2M-BBM.1 antibody complex reveals the molecular basis of antigen recognition, showing that specific complementarity-determining regions (CDRs) form hydrogen bonds and van der Waals contacts with B2M. Computational evolution of B2M-binding peptides has identified sequence motifs that enhance binding affinity for nanopatterned surfaces. These studies highlight that binding is driven by shape complementarity and electrostatic interactions.
Conformational changes and aggregation
In simple terms: B2M can change shape and clump together, and binding partners can influence this process.
A self-consistent molecular mechanism of B2M aggregation proposes that partial unfolding exposes aggregation-prone regions, leading to fibril formation. Strong acids induce amyloid fibril formation of B2M via an anion-binding mechanism, suggesting that binding of small anions can trigger conformational changes. These findings indicate that B2M binding events can either stabilize or destabilize the native fold.
Engineered binding proteins and nanoparticles
In simple terms: Scientists design proteins that grab B2M for use in filters or sensors.
Design of B2M adsorbent protein nanoparticles demonstrates that engineered binding proteins can selectively capture B2M from solution. Computational evolution of B2M-binding peptides for nanopatterned surface sensors shows that binding affinity can be optimized for detection applications. These engineered systems rely on the same molecular principles as natural B2M-binding proteins.
Regulation of B2M binding in disease
In simple terms: In some diseases, the amount of B2M or its binding partners changes, affecting how much binding occurs.
Serum B2M binding activity is altered in patients with systemic lupus erythematosus, suggesting that autoantibodies or other factors modulate binding. Urinary B2M increases after unilateral nephrectomy, reflecting changes in renal handling and potentially binding interactions in the kidney. These clinical observations link B2M binding to disease states.
Key Genes Involved in GO:0030881 beta-2-microglobulin binding
The following genes and proteins are directly involved in or studied in the context of beta-2-microglobulin binding (GO:0030881).
| Gene | Major Role | Research Relevance |
|---|---|---|
| B2M | Beta-2-microglobulin, the ligand for GO:0030881 | Central to MHC class I, amyloidosis, kidney injury |
| HLA-A | MHC class I heavy chain that binds B2M | Antigen presentation, immune recognition |
| HLA-B | MHC class I heavy chain that binds B2M | Antigen presentation, immune recognition |
| HLA-C | MHC class I heavy chain that binds B2M | Antigen presentation, immune recognition |
| BBM.1 | Antibody that binds B2M | Structural basis of antigen recognition |
| TIMP-2 | Inhibitor of metalloproteinases, related to kidney injury | Declines after nephrectomy alongside B2M changes |
| IGFBP7 | Insulin-like growth factor binding protein 7 | Kidney injury marker, related to B2M |
| MHC class I | Complex including B2M and heavy chain | Antigen presentation |
| CD8 | T cell co-receptor that recognizes MHC class I | Immune response to B2M-bound complexes |
| TCR | T cell receptor recognizing MHC class I | Immune recognition |
| Beta-2-microglobulin peptides | Engineered peptides binding B2M | Sensor design, computational evolution |
| B2M adsorbent nanoparticles | Engineered nanoparticles binding B2M | Adsorbent design |
| Anion-binding proteins | Proteins that bind anions and influence B2M aggregation | Amyloid fibril formation |
| Serum binding factors | Proteins in serum that bind B2M | SLE binding activity |
| Urinary B2M | B2M in urine | Kidney injury marker |
| Amyloid fibril proteins | Proteins forming fibrils with B2M | Dialysis-related amyloidosis |
| MHC class I heavy chain | Binds B2M for antigen presentation | Immune function |
| Antibody CDRs | Complementarity-determining regions binding B2M | Antibody engineering |
How Is beta-2-microglobulin binding Regulated?
Regulation of beta-2-microglobulin binding is not well-defined as a single pathway, but several factors influence it. Serum binding activity of B2M is altered in systemic lupus erythematosus, suggesting regulation by autoantibodies or inflammatory mediators. Urinary B2M levels change after nephrectomy, indicating renal handling and possibly binding interactions in the kidney. Strong acids and anions can induce conformational changes that promote B2M aggregation, which may compete with or alter binding to other proteins. Additionally, the design of B2M adsorbent nanoparticles suggests that binding can be engineered and regulated at the protein level.
beta-2-microglobulin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B2M | Dialysis-related amyloidosis | Knock-in mouse expressing human B2M, aggregation assays |
| B2M | Systemic lupus erythematosus | Patient serum binding assays, SLE mouse models |
| B2M | Kidney injury | Unilateral nephrectomy models, urinary B2M measurement |
| HLA-A | Antigen presentation defects | CRISPR knockout of HLA-A in cell lines |
| BBM.1 | Antibody-antigen recognition | Crystal structure, mutagenesis of CDRs |
Systemic lupus erythematosus (SLE)
Serum B2M binding activity is altered in patients with SLE, indicating that B2M interactions may contribute to autoimmune pathology. The binding activity could reflect autoantibodies or other serum factors that modulate B2M function.
Dialysis-related amyloidosis
B2M aggregation into amyloid fibrils is a hallmark of dialysis-related amyloidosis, and strong acids can induce fibril formation via an anion-binding mechanism. Understanding B2M binding and aggregation is critical for developing therapeutic strategies.
Kidney injury and nephrectomy
Urinary B2M increases after unilateral nephrectomy, while TIMP-2 and IGFBP7 decline, suggesting that B2M binding and excretion are altered in kidney injury. B2M is a widely used biomarker for renal tubular function.
From beta-2-microglobulin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of B2M affect binding to MHC class I? | B2M knockout cell lines |
| Can point mutations in B2M alter antibody binding? | Point-mutation knock-in of B2M variants |
| Can engineered B2M-binding peptides be expressed in cells? | Knock-in of peptide sequences |
| Does overexpression of B2M increase aggregation? | Overexpression cell models |
| What genes regulate B2M binding and presentation? | CRISPR library screening |
| Can B2M adsorbent nanoparticles be tested in vivo? | Animal models with B2M infusion |
How to Study the beta-2-microglobulin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of B2M-antibody complex | Binding interface mapping |
| Surface plasmon resonance | Binding affinity and kinetics | Engineered peptide optimization |
| ELISA | B2M binding activity in serum | SLE patient samples |
| Molecular dynamics | Aggregation mechanism | Amyloid fibril formation |
| CRISPR knockout | Loss-of-function of B2M or partners | MHC class I studies |
| CRISPR library screening | Genes regulating B2M binding | Functional genomics |
| Urinary B2M assay | Kidney injury marker | Nephrectomy follow-up |
| Nanoparticle adsorption | B2M capture efficiency | Adsorbent design |
Structural biology (X-ray crystallography, cryo-EM)
Crystal structure of the B2M-BBM.1 antibody complex reveals the molecular basis of antigen recognition at atomic resolution. These methods identify binding interfaces and guide mutagenesis.
Binding assays (SPR, ELISA, flow cytometry)
Serum B2M binding activity in SLE patients was measured using binding assays. Engineered B2M-binding peptides are tested for affinity using surface plasmon resonance or similar methods.
Computational design and evolution
Computational evolution of B2M-binding peptides for nanopatterned surface sensors uses in silico screening and optimization. Molecular dynamics simulations provide a self-consistent mechanism of B2M aggregation.
CRISPR screening and functional genomics
CRISPR library screening can identify genes that regulate B2M binding and presentation. Knockout of B2M or MHC class I genes validates binding partners.
How CRISPR Can Be Used to Study GO:0030881 beta-2-microglobulin binding
Knockout
CRISPR knockout of B2M or MHC class I genes can abolish B2M binding to heavy chains, providing a clean background to study binding specificity. Knockout of candidate genes identified in screens can validate their role in B2M binding.
Point Mutation
Point mutations in B2M or antibody CDRs can be introduced to test which residues are critical for binding, as guided by crystal structures. Such mutations can also model disease-associated variants.
Knock-in
Knock-in of engineered B2M-binding peptides or tagged B2M allows tracking of binding interactions in live cells. Knock-in of human B2M into mouse models can mimic human amyloidosis.
Overexpression
Overexpression of B2M or binding partners can drive aggregation or enhance binding signals for detection. Overexpression models are useful for studying amyloid formation and binding saturation.
How EDITGENE Supports beta-2-microglobulin binding Research
Researchers studying beta-2-microglobulin binding-related genes often need to determine whether a candidate gene is causally involved in binding, aggregation, or immune recognition. EDITGENE provides comprehensive CRISPR services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for beta-2-microglobulin binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CD1D Knockout HEK293 Cell Line | EDJ-KQ423 | Human | 912 | Details Get a Quote |
| HFE Knockout HEK293 Cell Line | EDJ-KQ1908 | Human | 3077 | Details Get a Quote |
| FCGRT Knockout HEK293 Cell Line | EDJ-KQ4579 | Human | 2217 | Details Get a Quote |
| MR1 Knockout HEK293 Cell Line | EDJ-KQ4880 | Human | 3140 | Details Get a Quote |
| HLA-G Knockout HEK293 Cell Line | EDJ-KQ4902 | Human | 3135 | Details Get a Quote |
| MICA Knockout HEK293 Cell Line | EDJ-KQ11941 | Human | 100507436 | Details Get a Quote |
| HLA-F Knockout HEK293 Cell Line | EDJ-KQ13015 | Human | 3134 | Details Get a Quote |
| HLA-A Knockout HEK293 Cell Line | EDJ-KQ13752 | Human | 3105 | Details Get a Quote |
| HLA-B Knockout HEK293 Cell Line | EDJ-KQ13753 | Human | 3106 | Details Get a Quote |
| HLA-C Knockout HEK293 Cell Line | EDJ-KQ13754 | Human | 3107 | Details Get a Quote |
| HLA-E Knockout HEK293 Cell Line | EDJ-KQ13757 | Human | 3133 | Details Get a Quote |
| FCGRT Knockout HeLa Cell Line | EDJ-KQ25984 | Human | 2217 | Details Get a Quote |
| MICA Knockout HeLa Cell Line | EDJ-KQ39212 | Human | 100507436 | Details Get a Quote |
| HFE Knockout A-549 Cell Line | EDJ-KQ21818 | Human | 3077 | Details Get a Quote |
| HFE Knockout HCT 116 Cell Line | EDJ-KQ21819 | Human | 3077 | Details Get a Quote |
Displaying Records 1 To 15 Of 47 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About beta-2-microglobulin binding
What is beta-2-microglobulin binding?
Beta-2-microglobulin binding (GO:0030881) is a molecular function where a protein or peptide selectively binds to beta-2-microglobulin (B2M).
What genes are involved in beta-2-microglobulin binding?
Key genes include B2M itself, MHC class I heavy chains (HLA-A, HLA-B, HLA-C), and antibody genes such as BBM.1.
What diseases are associated with beta-2-microglobulin binding?
Diseases include systemic lupus erythematosus, dialysis-related amyloidosis, and kidney injury.
How is beta-2-microglobulin binding studied?
It is studied using X-ray crystallography, binding assays, computational design, and CRISPR screens.
What is the role of B2M in the immune system?
B2M is the invariant light chain of MHC class I molecules and is essential for antigen presentation to T cells.
Can beta-2-microglobulin binding be targeted therapeutically?
Yes, engineered B2M adsorbent nanoparticles and binding peptides are being developed for therapeutic and diagnostic applications.
What is the link between B2M and amyloidosis?
B2M can aggregate into amyloid fibrils, especially in dialysis patients, and strong acids can induce this process via anion binding.
How does nephrectomy affect B2M levels?
Urinary B2M increases after unilateral nephrectomy, while TIMP-2 and IGFBP7 decline, indicating altered kidney handling.
What is the structure of the B2M-antibody complex?
The crystal structure of B2M with BBM.1 antibody reveals the molecular basis of antigen recognition.
What CRISPR models are available for B2M binding research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening models for B2M and related genes.
Conclusion
GO:0030881 beta-2-microglobulin binding is a molecular function with broad relevance to immunology, amyloidosis, and kidney disease. Understanding the structural and mechanistic basis of B2M binding can inform therapeutic design and diagnostic development. CRISPR-based models provide powerful tools to dissect these interactions and identify new targets.
References
- 1. Miller JE et al.. 2023. Design of Beta-2 Microglobulin Adsorbent Protein Nanoparticles.. Biomolecules 13(7) PMID: 37509158
- 2. Tammara V et al.. 2024. A Self-Consistent Molecular Mechanism of β(2)-Microglobulin Aggregation.. J Phys Chem B 128(50):12425-12442 PMID: 39656191
- 3. Adedeji Olulana AF et al.. 2021. Computational Evolution of Beta-2-Microglobulin Binding Peptides for Nanopatterned Surface Sensors.. Int J Mol Sci 22(2) PMID: 33467468
- 4. Evrin PE et al.. 1984. Beta 2-microglobulin and its binding activity in serum from patients with SLE.. Ann Rheum Dis 43(2):267-74 PMID: 6370153
- 5. Yamaguchi K et al.. 2021. Strong acids induce amyloid fibril formation of β(2)-microglobulin via an anion-binding mechanism.. J Biol Chem 297(5):101286 PMID: 34626645
- 6. de Rooij ENM et al.. 2024. Urinary beta-2 microglobulin increases whereas TIMP-2 and IGFBP7 decline after unilateral nephrectomy in healthy kidney donors.. Sci Rep 14(1):12901 PMID: 38839764
- 7. Revillard JP et al.. 1976. [Beta 2 microglobulin].. Nouv Presse Med 5(40):2707-12 PMID: 63940
- 8. Wu J et al.. 2025. Crystal structure of the β(2)-microglobulin-BBM.1 antibody complex reveals the molecular basis of antigen recognition.. Acta Crystallogr D Struct Biol 81(Pt 9):473-481 PMID: 40748259
